美国联邦医疗保险人群中原发性胆汁性胆管炎对死亡率和资源利用的影响
本研究利用2005至2015年美国联邦医疗保险受益人的5%随机样本数据,以ICD-9编码571.6诊断原发性胆汁性胆管炎,评估该人群死亡率和医疗资源利用趋势。共纳入6375例住院或门诊受益人,平均年龄69.8岁,男性占17%,白人占88%,18%有残疾。研究期间1年死亡率保持稳定(9.1%至14.3%,P=0.11),但门诊和住院的年度总费用与支付额均显著上升。
要点
- 美国联邦医疗保险受益人中原发性胆汁性胆管炎患病率上升。
- 研究期间1年死亡率保持稳定(9.1%至14.3%,P=0.11)。
- 门诊和住院的年度总费用与支付额均随时间显著增加。
核心结论
- 美国联邦医疗保险受益人中原发性胆汁性胆管炎的患病率有所增加,尽管死亡率保持稳定,但该人群的医疗资源利用持续上升。
研究设计与样本
- 研究使用2005至2015年美国联邦医疗保险受益人5%随机样本数据,以国际疾病分类第9版编码571.6(用于主要和次要诊断)确立原发性胆汁性胆管炎诊断。
- 研究队列共纳入6375例住院或门诊医疗保险受益人,平均年龄69.8岁,男性占17%,白人占88%,18%有残疾。
- 死亡率通过医疗保险关联的死亡登记评估,医疗资源利用包括诊疗次数、住院时长和总费用与支付额,采用多因素广义线性或逻辑回归模型评估独立预测因素。
主要发现
- 研究期间1年死亡率保持稳定,范围为9.1%至14.3%(P=0.11)。
- 1年死亡率的独立预测因素包括年龄较大、男性、黑人种族、存在腹水、肝性脑病、肝细胞癌和较高的Charlson评分。
- 每名受益人门诊年度总费用从2005年的3065美元增至2014年的5773美元,门诊年度总支付额从777美元增至967美元。
- 每名受益人住院年度总费用从2007年的59765美元增至2013年的98941美元,住院年度总支付额从19406美元增至27948美元(P<0.05)。
- 腹水、门静脉高压和较高的Charlson评分是住院和门诊资源利用支付额较高的独立预测因素,肝性脑病是住院资源利用支付额较高的额外预测因素(所有P<0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is a disease of small bile ducts, which can lead to morbidity and mortality. Our aim was to assess recent trends in mortality and healthcare use of PBC patients in the Medicare program. Data from Medicare beneficiaries between 2005 and 2015 (5% random samples) were used. The diagnosis of PBC was established with International Classification of Diseases-9 code 571.6 used for both primary and secondary diagnoses. Mortality was assessed by Medicare-linked death registry. Healthcare use included episodes of care, length of stay, and total charges/payments. Independent predictors of outcomes were evaluated in multiple generalized linear or logistic regression models. The study cohort included a total of 6,375 inpatient/outpatient Medicare beneficiaries (mean age 69.8 years, 17% male, 88% white, and 18% with disability). Over the study period, 1-year mortality remained stable (9.1% to 14.3%, P = 0.11). Independent predictors of 1-year mortality were older age, male gender, black race, the presence of ascites, encephalopathy, hepatocellular carcinoma, and higher Charlson score. Outpatient total yearly charges and payments per beneficiary with PBC increased from $3,065 and $777 (2005) to $5,773 and $967 (2014), respectively. Similarly, inpatient total yearly charges and payments per beneficiary with PBC increased from $59,765 and $19,406 (2007), to $98,941 and $27,948 (2013), respectively (P < 0.05). The presence of ascites, portal hypertension, and higher Charlson score were independent predictors of higher payments for both inpatient and outpatient resource use, and the presence of hepatic encephalopathy was an additional predictor of higher inpatient resource use (all P < 0.02). Conclusion: The prevalence of PBC among the Medicare beneficiaries has increased. Despite stable mortality rates, resource use for Medicare patients with PBC continues to rise.
引用
- Sayiner M, Golabi P, Stepanova M, et al. Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. Hepatology. 2019. PMID: 30015376. doi:10.1002/hep.30174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。